A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

441

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: Tirzepatide
DRUG: Placebo

Sponsor

Eli Lilly and Company